CIM
BEAM icon

Contrarius Investment Management’s Beam Therapeutics BEAM Stock Holding History

Contrarius Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-126,968
Closed -$3.05M – 56
2023
Q3 		$3.05M Buy
126,968
+13,604
+12% +$365K 0.17% 47
2023
Q2 		$3.62M Buy
+113,364
New +$3.68M 0.19% 45

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Contrarius Investment Management's BEAM Position: Q4 2023 in Review

Contrarius Investment Management sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 126,968 shares — an estimated $3.05M sold.

Contrarius Investment Management first reported a position in BEAM in Q2 2023 and held it in 2 quarters. The position peaked at $3.62M in Q2 2023. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

  • Contrarius Investment Management reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Contrarius Investment Management sold 126,968 Beam Therapeutics shares in Q4 2023, an estimated $3.05M.
  • Contrarius Investment Management first reported a position in Beam Therapeutics in Q2 2023 and held it in 2 quarters.
  • Contrarius Investment Management's Beam Therapeutics position peaked at $3.62M in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on Contrarius Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.